

Bioadaptives, Inc.

Amendment to [Management Certification](#) for 12/31/2025 originally published through the OTC Disclosure & News Service on 05/15/2026

Explanatory Note:

Updated Management Report for period ending 12-31-2025

***This coversheet was automatically generated by OTC Markets Group based on the information provided by the Company. OTC Markets Group has not reviewed the contents of this amendment and disclaims all responsibility for the information contained herein.*

Management Certification

The undersigned, on behalf of BioAdaptives Inc ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

SEC Reporting Obligations

- The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- The Company has a reporting obligation under Regulation A (Tier 2)
- The Company has a reporting obligation under Regulation Crowdfunding (CF)
- Other (please describe)

Other Reporting Obligations

- The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard

2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes: No:

4. The Company has a Verified Company Profile on OTCMarkets.com.

5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.

6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.

7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.

8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.¹

Transfer Agent: Dominion Stock transfer Inc
Address: 1900 Glades Rd, 4th Floor, Boca Raton, FL 33431

¹ OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

Pubco Reporting Services Inc, Accounting Boladale Lawal & Co (Chartered Accountants), PCAOB Auditors

10. The Company's Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): March 31, 2025

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Azuna Health (James E Keener)	CEO & Chair BoD	Las Vegas, NV	1,000,000	Series C	100%
James E Keener	CEO & Chair BoD	Las Vegas, NV	132,096	Series D	49.4%
Gimhana Dissanayake	Director	Las Vegas, NV	37,875	Series D	14.2%
Mark Frissora	Director	Naples, FL	63,836	Series D	23.9%
Mary Wilkins	Shareholder	Bend, OR	33,333	Series D	12.5%

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

11. The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ²	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
4/3/2018	10,000	10,000	4/3/2020	50% previous 30 day upon conversion request	0	2,978,723	Kim HockTham & PakYuk Tan Trust	Loan-convertible debenture
4/6/2018	50,000	50,000	4/6/2020	50% previous 30 day upon conversion request	0	14,621,277	2018 Tina Tianxin Liang Trust	Loan-convertible debenture
4/9/2018	5,000	5,000	4/9/2020	50% previous 30 day upon conversion request	0	1,441,702	Ang Li	Loan-convertible debenture
4/9/2018	5,000	5,000	4/9/2020	50% previous 30 day upon conversion request	0	1,461,277	Shuang Wang	Loan-convertible debenture
4/15/2018	25,000	25,000	4/15/2020	50% previous 30 day upon conversion request	0	7,297,872	Hong Yu	Loan-convertible debenture
6/1/2018	50,000	50,000	6/1/2020	50% previous 30 day upon conversion request	0	14,468,085	Fri & Scott Havenor	Loan-convertible debenture

Any additional material details, including footnotes to the table are below :

² The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ³	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
6/1/2018	25,000	25,000	6/12/2020	50% previous 30 day upon conversion request	0	7,234,043	XiaoKui Ma	Loan-convertible debenture
6/12/2018	5,000	5,000	6/12/2020	50% previous 30 day upon conversion request	0	1,443,404	Xiao Yun Pan	Loan-convertible debenture
6/18/2018	5,000	5,000	6/18/2020	50% previous 30 day upon conversion request	0	1,489,362	Ang Li	Loan-convertible debenture
6/19/2018	50,000	50,000	6/19/2020	50% previous 30 day upon conversion request	0	14,446,298	Stephanie Shao	Loan-convertible debenture
6/21/2018	6,000	6,000	6/21/2020	50% previous 30 day upon conversion request	0	1,729,021	LiYing Wang	Loan-convertible debenture
6/21/2018	25,000	25,000	6/21/2020	50% previous 30 day upon conversion request	0	7,204,255	Yuqi Wang	Loan-convertible debenture
10/24/2018	50,000	50,000	9/2/2020	50% previous 30 day upon conversion request	0	14,059,574	Weijia Qi	Loan-convertible debenture
11/5/2024	150,000	16,200	5/5/2025	Average price of previous 15 day upon conversion request	2,960,000	1,673,776	Valerian Capital LLC, Daniel Friday	Loan-convertible debenture
11/24/2025	82,500	82,500	11/24/2026	60% lowest price for previous 20 day upon	0	13,133,846	Jefferson Street Capital LLC, Brian Goldberg	Loan-convertible debenture
11/25/2025	130,000	130,000	11/25/2026	60% previous 20 60% lowest price	0	22,115,333	CFI Capital LLC, Ahron Fraiman	Loan-convertible debenture

³ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

				for previous 20 day upon				
11/26/2025	82,500	82,500	11/26/2026	60% lowest price for previous 20 day upon		13,126,923	Lambda Venture Partners LLC, Andrew Avitan	Loan-convertible debenture

Total Outstanding Balance: 622,200

Total Shares: 2,960,000 139,924,771

Signature:

Name of Principal Executive Officer or Principal Financial Officer: James Keener

Title: CEO

Date: May 15, 2026

Signature: /s/ James Keener

(Digital Signatures should appear as "/s/ [OFFICER NAME]")